Checkpoint Capital L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001977548

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q1 2024 · 17 positions · Total reported value $149.63M · Top-10 concentration 92.2% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 25.0% · 2 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q1 2024 13F filing, Checkpoint Capital L.P. disclosed 17 equity positions with a combined reported value of $149.63M. The filing implies a focused portfolio: its ten largest positions account for 92.2% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2024 were RYTM ($35.77M), ARGX ($32.29M), CYTK ($13.32M). By sector, the heaviest allocations are Health Care 90.4%, Other 9.6%. Versus the prior quarter, allocation shifted toward Health Care (+12.6pp) and away from Other (-12.6pp).

Versus the prior quarter, Checkpoint Capital L.P. opened 2 new positions, trimmed 0 and fully exited 0, a turnover rate of 25.0% of positions. The portfolio's overlap with the prior quarter was 59% of names.

The largest new positions opened in Q1 2024 were CORT ($6.90M), VSTM ($1.99M), APLT ($1.50M).

Of the 5 positions fully exited versus the prior quarter, the largest were XBI ($16.07M), SWTX ($12.41M), IRON ($577.60K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2024)

  • CORT CORCEPT THERAPEUTICS INC · $6.90M
  • VSTM VERASTEM INC · $1.99M
  • APLT APPLIED THERAPEUTICS INC · $1.50M
  • ATRA ATARA BIOTHERAPEUTICS INC · $619.64K

Fully Exited (vs previous quarter)

  • XBI SPDR SERIES TRUST · prev qtr: $16.07M
  • SWTX SPRINGWORKS THERAPEUTICS INC · prev qtr: $12.41M
  • IRON DISC MEDICINE INC · prev qtr: $577.60K · history
  • ACRS ACLARIS THERAPEUTICS INC · prev qtr: $476.30K
  • EWTX EDGEWISE THERAPEUTICS INC · prev qtr: $361.02K

Insider Transactions (Form 4)

Latest Checkpoint Capital L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Checkpoint Capital L.P., based in San Francisco, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 6 positions worth $389.76M in total. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Firm Snapshot

  • Headquarters: SAN FRANCISCO, CA, United States
  • SEC registration: 801-134055 (status: Approved), registered 2025-08-19
  • Regulatory AUM (Form ADV): $333.78M as of 2026-03-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds
  • Website: checkpointlp.com

Portfolio Structure

  • 6 positions · $389.76M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: RYTM (RHYTHM PHARMACEUTICALS INC) at 33.8%
  • Average position size: $64.96M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 3 added, 3 reduced, 2 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 90.4%
Other 9.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 825.50K $35.77M 23.91%
23.91%
Add
2 82.00K $32.29M 21.58%
21.58%
Add
3 190.00K $13.32M 8.90%
8.90%
Reduce
4 701.39K $11.85M 7.92%
7.92%
Add
5 132.44K $10.57M 7.06%
7.06%
Reduce
6 362.19K $9.10M 6.08%
6.08%
Add
7 280.30K $8.11M 5.42%
5.42%
Add
8 273.78K $6.90M 4.61%
4.61%
New
9 618.53K $5.39M 3.60%
3.60%
Add
10 445.16K $4.73M 3.16%
3.16%
Add
11 1.45M $2.82M 1.89%
1.89%
Reduce
12 168.74K $1.99M 1.33%
1.33%
New
13 185.65K $1.98M 1.32%
1.32%
Reduce
14 506.08K $1.75M 1.17%
1.17%
Reduce
15 220.00K $1.50M 1.00%
1.00%
New
16 767.96K $967.63K 0.65%
0.65%
Add
17 892.85K $619.64K 0.41%
0.41%
New

FAQ

What did Checkpoint Capital L.P. buy in 2024-Q1?

In its 2024-Q1 13F filing, Checkpoint Capital L.P. reported 17 equity positions worth $149.63M in aggregate; its largest disclosed positions were RYTM ($35.77M), ARGX ($32.29M), CYTK ($13.32M).

How large is Checkpoint Capital L.P.'s portfolio?

Checkpoint Capital L.P. reported $149.63M of long equity holdings across 17 positions as of 2024-Q1. Top-10 holdings account for 92.2% of reported value.

What is Checkpoint Capital L.P.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/checkpoint-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →